Health Condition 1: I10- Essential (primary) hypertension
Conditions
Interventions
Intervention1: Azilsartan: The group I patients will receive Azilsartan 40-80 mg OD by oral route. The dose will be adjusted according to the severity of hypertension. The therapeutic efficacy of dru
Sponsors
PIMS
Eligibility
Inclusion criteria
Inclusion criteria: New patients with hypertension i.e not on any antihypertensive therapy. 2. Adult males and females of age 18 years or more.
Exclusion criteria
Exclusion criteria: 1.Sitting clinic diastolic BP (DBP) >114ââ?¬Æ?mm Hg 2.Patients already on anti-hypertensives. 3.Patients with hypersensitivity to AZL or Losartan. 4.Pregnant/ lactating women/ women planning to conceive. 5.Evidence of severe renal disorder. 6.Patients with hepatic insufficiencies. 7.Patients unwilling or unable to comply with the study proceedings. 8.Patients with severe bradycardia, cardiogenic shock, heart block, sick sinus syndrome, decompensated heart failure, bronchial asthma, hypothyroidism, CVA, CAD. 9.Patients with other co morbidities like hyperthyroidism, anxiety disorders. 10.Patients with refractory hypertension.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The end point of the study is attainment of BP 140/90 mmHg for all patients and then maintains it.Timepoint: The SBP will be measured at the end of 24 weeks and compared between the two groups. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Responders and Non-responders will be identified. Responders- those patients whose clinic SBP falls to 140mm of Hg with maximum dose and/or reduced by ââ?°Â¥20ââ?¬Æ?mm Hg from baseline within one month are classed as responders while those patients whose clinic systolic blood pressure does not fall to 140mm of HG with maximum dose within one month are classed as non-responders.Timepoint: 1 month;Following base line investigations will be carried out at the commencement of treatmentââ?¬â?hemoglobin (Hb), total leucocyte count (TLC), differential leucocyte count (DLC), fasting blood sugar (FBS), Blood Urea, uric acid, Serum Creatinine, serum electrolytes, liver function test (LFT), Lipidogram, echocardiography (ECG) and urine routine examination (R/E). At the end of the treatment the investigations will be repeated and compared with the previous ones.Timepoint: 24 week;Patient acceptance of treatment on three point scale will be recorded at the end of treatment at 24 week. 0--Not acceptable 1-- Accepted with discomfort 2--- Very well accepted Timepoint: 24 week | — |
Countries
India
Contacts
Public ContactBaljit Jassal
Punjab Institute of Medical Sciences
Outcome results
None listed